- Home
- NUWE vs INM Comparison
NUWE vs INM Comparison
Compare NUWE & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- INM
- Stock Information
- Founded
- NUWE 1999
- INM 1981
- Country
- NUWE United States
- INM Canada
- Employees
- NUWE N/A
- INM N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- INM Health Care
- Exchange
- NUWE Nasdaq
- INM Nasdaq
- Market Cap
- NUWE 3.9M
- INM 3.2M
- IPO Year
- NUWE N/A
- INM N/A
- Fundamental
- Price
- NUWE $0.40
- INM $2.87
- Analyst Decision
- NUWE Strong Buy
- INM
- Analyst Count
- NUWE 1
- INM 0
- Target Price
- NUWE $17.00
- INM N/A
- AVG Volume (30 Days)
- NUWE 187.8K
- INM 4.1M
- Earning Date
- NUWE 05-13-2025
- INM 05-12-2025
- Dividend Yield
- NUWE N/A
- INM N/A
- EPS Growth
- NUWE N/A
- INM N/A
- EPS
- NUWE N/A
- INM N/A
- Revenue
- NUWE $8,787,000.00
- INM $4,920,990.00
- Revenue This Year
- NUWE $26.81
- INM N/A
- Revenue Next Year
- NUWE $48.74
- INM N/A
- P/E Ratio
- NUWE N/A
- INM N/A
- Revenue Growth
- NUWE N/A
- INM N/A
- 52 Week Low
- NUWE $0.40
- INM $1.72
- 52 Week High
- NUWE $8.40
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- NUWE 15.96
- INM 50.24
- Support Level
- NUWE $0.76
- INM $2.74
- Resistance Level
- NUWE $0.95
- INM $3.45
- Average True Range (ATR)
- NUWE 0.09
- INM 0.70
- MACD
- NUWE -0.05
- INM 0.03
- Stochastic Oscillator
- NUWE 0.00
- INM 9.40
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.